SD Biosensor Acquires German In Vitro Diagnostics Distributor for 16.1 Billion KRW
[Asia Economy Reporter Lee Gwan-joo] SD Biosensor announced on the 30th that it acquired the German in vitro diagnostics distributor 'Bestbion' for 16.1 billion KRW.
Founded in 2011, the German distribution company 'Bestbion' has established its own distribution network capable of delivering within 24 hours throughout Germany and Austria. It distributes immunodiagnostics, microbiology, infectious disease, and molecular diagnostic products, including those for rare diseases, and has maintained a dealership with SD Biosensor since 2018, mainly supplying the fluorescent immunodiagnostic brand 'STANDARD F' products.
SD Biosensor judged that 'Bestbion,' which has secured more than 1,000 major clients including large testing centers, university hospitals, and government agencies in Europe, would serve as a foundation to expand the company's presence across various diagnostic platforms in the European market.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Samsung Labor-Management 'Performance Bonus Negotiations' Fail in Third Mediation... Union Says "General Strike to Proceed as Planned Tomorrow"
- [Breaking] Blue House: "Deeply Regret Central Labor Relations Commission Post-Mediation Breakdown... Urge Labor and Management to Do Their Best Until the End"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
An SD Biosensor official stated, “Through the M&A of the German distributor, SD Biosensor has saved the time required to establish a local corporation and has entered the European market more effectively. We plan to continue expanding distribution networks not only in Germany but also in other regions, and in the future, through strategic partnerships with telemedicine companies within Europe, we will broaden our scope beyond COVID-19 products to general diseases.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.